Results
Nasal Obstruction
ADVERSE EVENTS, SECONDARY, RECRUITMENT
Between 26 January 2018 and 5 December 2019, 378 eligible participants (67% men) were randomised. Baseline personal characteristics were balanced across treatment groups (Baseline characteristics of recruited participants. Values are number (percentage) unless stated otherwiseIQR=interquartile range; NOSE Nasal Obstruction and Symptom Evaluation scale; SD=standard deviation.The onset of the covid-19 pandemic resulted in the suspension of all face-to-face clinics from 30 March 2020, therefore remaining trial participants were invited to complete the primary outcome six month SNOT-22 measure (n=8, 2%) and the secondary outcome 12 month SNOT-22 measure (n=25, 7%) remotely. By then recruitment had been achieved and all trial interventions had been completed. Information on adverse events was collected remotely by telephone at the six month and 12 month follow-ups. Only 66 participants in the septoplasty group and 72 in the medical management group completed the 12 month objective flow measures.Four SNOT-22 questionnaires had missing items at baseline—two in each treatment group (1%), five at the primary six month endpoint (2%) and four at the final 12 month data collection point (1%). All of these were imputed as each had <20% missing. One participant had one item missing from the NOSE scale questionnaire (20%) at the six month follow-up. This was also imputed, using the mean of the other four responses.